Functional testing of relapsed chronic lymphocytic leukemia guides precision medicine and maps response and resistance mechanisms. An index case

Haematologica. 2022 Aug 1;107(8):1994-1998. doi: 10.3324/haematol.2021.280393.
No abstract available

MeSH terms

  • Drug Resistance, Neoplasm / genetics
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell* / diagnosis
  • Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
  • Leukemia, Lymphocytic, Chronic, B-Cell* / genetics
  • Precision Medicine
  • Recurrence
  • Rituximab


  • Rituximab

Grants and funding

Funding: The work was supported by the Research Council of Norway under the frame of ERA PerMed (to SSS, project number 322898), Lilly Constance og Karl Ingolf Larssons stiftelse (to SSS), and Stiftelsen Kristian Gerhard Jebsen (to GET and LAM, grant 19).